Osteoarthritis (OA) is one of the major degenerative diseases of our time, affecting millions of people around the world and leading to a significant decrease in quality of life. At Bioclinica's Research Network, we have a long track record of recruiting large numbers of qualified patients for OA studies and seeing them successfully through trial completion.

Deep Expertise
Bioclinica has conducted 63 OA studies, ranging from Phase I to Phase IV. Over the course of these studies, we have worked with a variety of compounds and routes of administration, including ultrasound-guided intra-articular administration. Site staff are familiar with multiple OA assessment questionnaires, such as WOMAC, PGA, and PD-Q. Our Key Opinion Leader in OA has published multiple papers on the topic, leading to a greater understanding of the disease and its treatment.

Number of OA Studies Completed to Date
- Phase I – 2 studies
- Phase II – 27 studies
- Phase III – 29 studies
- Phase IV – 2 studies
- N/A – 3 study
Patient Recruitment and Retention

With OA studies, it is imperative to process high volumes of patients in as few sites as possible to decrease the variability of the data and keep costs under control. At Bioclinica, we are able to do exactly that. Our databases contain large numbers of patients at various stages of OA as determined by the Kellgren-Lawrence (KL) grading scale. Over the years, we have screened over 7000 patients and randomized almost 4500.

Of equal importance is patient retention. OA studies are often plagued by patients dropping out of the trials. We believe that retention starts with recruitment, so we screen patients very carefully to determine their willingness to stay the course of the trial. We then engage with and care for them to encourage their continued participation, ensuring the on-time completion of your study.

The cornerstone of effective retention is education and communication. We have a dedicated recruitment team that educates patients from the first contact. During screening, patients are given a visit calendar which is signed by both the patient and the coordinator. At screening and all subsequent visits, the physician speaks with the patient about trial commitment. After randomization, we keep in regular contact with patients - especially if the duration of time between visits is lengthy.

Bioclinica’s Research Network was contracted to enroll 535 subjects across 8 sites during the course of 9 months. Through extensive pre-identification, we were able to enroll the first subject 1 month ahead of schedule. Patient recruitment continued at a swift pace, allowing the sponsor to close global enrollment 6 weeks ahead of schedule.

Number of subjects enrolled per site

<table>
<thead>
<tr>
<th>Number of subjects</th>
<th>Bioclinica</th>
<th>Non-Bioclinica</th>
</tr>
</thead>
<tbody>
<tr>
<td>Range</td>
<td>0-70</td>
<td>0-10</td>
</tr>
</tbody>
</table>

North America: +1 267-757-3319 / Europe: +41 21-588-0620 / research.network@bioclinica.com / bioclinica.com